Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF) Sees Significant Increase in Short Interest
Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF) Sees Significant Increase in Short Interest
Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF – Get Rating) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,500 shares, an increase of 1,400.0% from the July 31st total of 100 shares. Based on an average daily volume of 2,300 shares, the short-interest ratio is presently 0.7 days.
Ortho Regenerative Technologies Inc.(OTCMKTS：ORIF-GET Rating)是8月份空头股数大幅上涨的接受者。截至8月15日，空头股数共有1,500股，比7月31日的100股增加了1,400.0%。以日均成交量2,300股计算，目前短息比率为0.7天。
Ortho Regenerative Technologies Price Performance
正射再生技术性价比
OTCMKTS:ORTIF remained flat at $0.20 on Friday. The company has a market cap of $6.86 million, a P/E ratio of -1.78 and a beta of -1.22. Ortho Regenerative Technologies has a 1 year low of $0.13 and a 1 year high of $0.45. The firm's fifty day moving average is $0.20 and its 200-day moving average is $0.19.
OTCMKTS：ORTIF周五持平于0.20美元。该公司的市值为686万美元，市盈率为-1.78，贝塔系数为-1.22。Ortho Regenerative Technologies的一年低点为0.13美元，一年高位为0.45美元。该公司的50日移动均线切入位为0.20美元，200日移动均线切入位为0.19美元。
Ortho Regenerative Technologies (OTCMKTS:ORTIF – Get Rating) last announced its quarterly earnings results on Thursday, June 23rd. The company reported ($0.02) EPS for the quarter. Analysts predict that Ortho Regenerative Technologies will post -0.08 earnings per share for the current fiscal year.
Ortho Regenerative Technologies(OTCMKTS：ORTIF-GET Rating)最近一次公布季度收益是在6月23日星期四。该公司公布了该季度每股收益(0.02美元)。分析师预测，Ortho Regenerative Technologies本财年的每股收益将为0.08美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Ortho Regenerative Technologies Company Profile
Ortho再生技术公司简介
(Get Rating)
(获取评级)
Ortho Regenerative Technologies Inc, an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration.
Ortho Regenerative Technologies Inc是一家整形外科和运动医学生物制剂公司，致力于研究和开发新型治疗性软组织修复技术，以提高加拿大运动医学手术的成功率。它开发了用于肩袖修复的Ortho-R配方、用于半月板修复的生物聚合物Ortho-M、用于关节软骨修复的生物聚合物Ortho-C、用于骨关节炎愈合的生物聚合物Ortho-V以及用于肌腱愈合和再生的生物聚合物配方Ortho-T。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Ortho Regenerative Technologies (ORTIF)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- 免费获取StockNews.com关于正畸再生技术的研究报告(ORTIF)
- 为什么进军高级汽车零部件可能是一个机会
- MarketBeat：回顾中的一周8/22-8/26
- 机构买入让Marvell科技陷入低谷
- 戴尔股票因销售疲软而回落，跌入可怕的价值
- Dollar General的拉力赛有三个理由
Receive News & Ratings for Ortho Regenerative Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ortho Regenerative Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《正畸再生技术日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ortho再生技术公司和相关公司的最新新闻和分析师评级的每日简要摘要。